Comparative Pharmacology
Head-to-head clinical analysis: DYMISTA versus KALLIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYMISTA versus KALLIGA.
DYMISTA vs KALLIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine is a histamine H1-receptor antagonist; fluticasone propionate is a corticosteroid with anti-inflammatory activity. The combination reduces nasal symptoms by blocking histamine receptors and inhibiting inflammatory mediators.
KALLIGA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and easily excreted metabolite, thereby reducing serum uric acid levels.
One spray (137 mcg azelastine hydrochloride/50 mcg fluticasone propionate) per nostril twice daily, intranasal.
0.5 mg orally once daily, titrated to 1 mg once daily after 2-4 weeks if tolerated.
None Documented
None Documented
Azelastine: terminal half-life ~22 hours (plasma) with long-lasting antihistamine effect. Fluticasone propionate: terminal half-life ~7.8 hours (intravenous), but intranasal systemic exposure is very low.
Terminal elimination half-life: 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min)
Azelastine: ~75% renal (primarily as parent and metabolites), ~25% fecal. Fluticasone propionate: <5% renal, >95% fecal as parent and metabolites.
Renal excretion: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Antihistamine/Corticosteroid Combination
Antihistamine